Visit-to-visit fasting plasma glucose variability is an important risk factor for long-term changes in left cardiac structure and function in patients with type 2 diabetes

[1] Grundy SM(1999)Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association Circulation 100 1134-1146

[2] Benjamin IJ(2008)Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programme Eur Heart J 29 1377-1385

[3] Burke GL(2017)Association of insulin resistance and glycemic metabolic abnormalities with LV structure and function in middle age: the cardia study JACC Cardiovasc Imaging. 10 105-114

[4] Chait A(2013)Differential changes of left ventricular myocardial deformation in diabetic patients with controlled and uncontrolled blood glucose: a three-dimensional speckle-tracking echocardiography-based study J Am Soc Echocardiogr 26 499-506

[5] Eckel RH(2016)Glycemic variability evaluated by continuous glucose monitoring system is associated with the 10-y cardiovascular risk of diabetic patients with well-controlled HbA1c Clin Chim Acta 461 146-150

[6] Howard BV(2014)Visit-to-visit variability of fasting plasma glucose as predictor of ischemic stroke: competing risk analysis in a national cohort of Taiwan Diabetes Study BMC Med. 12 165-1754

[7] MacDonald MR(1997)Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study Circulation 96 1750-128

[8] Petrie MC(2018)Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes Diabetes Metab 44 121-2365

[9] Varyani F(2016)Fasting plasma glucose variability and all-cause mortality among type 2 diabetes patients: a dynamic cohort study in Shanghai, China Sci Rep 6 39633-50

[10] Ostergren J(2014)Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial Diabetes Care 37 2359-553

[1] Grundy SM(1999)Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association Circulation 100 1134-1146

[2] Benjamin IJ(2008)Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) programme Eur Heart J 29 1377-1385

[3] Burke GL(2017)Association of insulin resistance and glycemic metabolic abnormalities with LV structure and function in middle age: the cardia study JACC Cardiovasc Imaging. 10 105-114

[4] Chait A(2013)Differential changes of left ventricular myocardial deformation in diabetic patients with controlled and uncontrolled blood glucose: a three-dimensional speckle-tracking echocardiography-based study J Am Soc Echocardiogr 26 499-506

[5] Eckel RH(2016)Glycemic variability evaluated by continuous glucose monitoring system is associated with the 10-y cardiovascular risk of diabetic patients with well-controlled HbA1c Clin Chim Acta 461 146-150

[6] Howard BV(2014)Visit-to-visit variability of fasting plasma glucose as predictor of ischemic stroke: competing risk analysis in a national cohort of Taiwan Diabetes Study BMC Med. 12 165-1754

[7] MacDonald MR(1997)Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study Circulation 96 1750-128

[8] Petrie MC(2018)Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes Diabetes Metab 44 121-2365

[9] Varyani F(2016)Fasting plasma glucose variability and all-cause mortality among type 2 diabetes patients: a dynamic cohort study in Shanghai, China Sci Rep 6 39633-50

[10] Ostergren J(2014)Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial Diabetes Care 37 2359-553